{"id":"placebo-tablet-and-budesonide","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oral candidiasis"},{"rate":"1-5","effect":"Tremor"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Dysphonia"},{"rate":"5-10","effect":"Throat irritation"},{"rate":null,"effect":"Systemic corticosteroid effects (with higher doses)"}]},"_chembl":{"chemblId":"CHEMBL1370","moleculeType":"Small molecule","molecularWeight":"430.54"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Budesonide binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and modulates gene transcription to decrease production of pro-inflammatory cytokines, chemokines, and adhesion molecules. This reduces airway inflammation, mucus production, and immune cell infiltration. The placebo control arm allows for comparison of budesonide's efficacy against baseline disease progression.","oneSentence":"Budesonide is a corticosteroid that reduces inflammation by suppressing immune response and inflammatory mediator production in the airways and gastrointestinal tract.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:31.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (maintenance therapy)"},{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Inflammatory bowel disease (Crohn's disease or ulcerative colitis)"}]},"trialDetails":[{"nctId":"NCT04314375","phase":"PHASE4","title":"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2023-09-29","conditions":"Ulcerative Colitis","enrollment":70},{"nctId":"NCT06895460","phase":"PHASE3","title":"A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-06-20","conditions":"Bronchial Asthma","enrollment":198},{"nctId":"NCT00092092","phase":"PHASE4","title":"Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-10","conditions":"Asthma, Bronchial","enrollment":71},{"nctId":"NCT04727424","phase":"PHASE3","title":"Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms","status":"RECRUITING","sponsor":"Cardresearch","startDate":"2021-01-19","conditions":"Covid19, SARS-Associated Coronavirus","enrollment":7819},{"nctId":"NCT02493335","phase":"PHASE3","title":"Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2016-01-15","conditions":"Eosinophilic Esophagitis","enrollment":204},{"nctId":"NCT00801723","phase":"PHASE3","title":"(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-12","conditions":"Ulcerative Colitis","enrollment":123},{"nctId":"NCT00679380","phase":"PHASE3","title":"(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-06","conditions":"Ulcerative Colitis","enrollment":514},{"nctId":"NCT00679432","phase":"PHASE3","title":"(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-06","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT01532648","phase":"PHASE3","title":"Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-01-27","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT02434029","phase":"PHASE3","title":"Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2015-11-11","conditions":"Eosinophilic Esophagitis","enrollment":88},{"nctId":"NCT00887263","phase":"PHASE3","title":"Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2009-03","conditions":"Oral Chronic Graft vs Host Disease","enrollment":186},{"nctId":"NCT02280616","phase":"PHASE2","title":"Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2011-06","conditions":"Eosinophilic Esophagitis","enrollment":76},{"nctId":"NCT01266772","phase":"PHASE3","title":"Effect of Montelukast in Asthma in Children","status":"UNKNOWN","sponsor":"Medical University of Lodz","startDate":"2011-01","conditions":"Bronchial Asthma","enrollment":160},{"nctId":"NCT01023516","phase":"PHASE2","title":"Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":615},{"nctId":"NCT00633919","phase":"PHASE2, PHASE3","title":"Efficacy of SLITone in House Dust Mite Allergic Patients","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2006-07","conditions":"Allergy","enrollment":124},{"nctId":"NCT01170429","phase":"PHASE4","title":"Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA)","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2010-07","conditions":"Cough Variant Asthma","enrollment":160},{"nctId":"NCT00504946","phase":"PHASE3","title":"Pharmacological Modulations of Allergen-Specific Immunotherapy","status":"COMPLETED","sponsor":"Medical University of Lodz","startDate":"2005-09","conditions":"Asthma","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo tablet and Budesonide."],"phase":"phase_3","status":"active","brandName":"Placebo tablet and budesonide","genericName":"Placebo tablet and budesonide","companyName":"Medical University of Lodz","companyId":"medical-university-of-lodz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide is a corticosteroid that reduces inflammation by suppressing immune response and inflammatory mediator production in the airways and gastrointestinal tract. Used for Asthma (maintenance therapy), Chronic obstructive pulmonary disease (COPD), Inflammatory bowel disease (Crohn's disease or ulcerative colitis).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}